deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02484430

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Sponsor: National Cancer Institute (NCI)

Conditions B Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Recurrent Adult Acute Lymphoblastic Leukemia Refractory Adult Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia
Interventions Laboratory Biomarker Analysis Pharmacological Study Sapanisertib
Updated 34 times since 2017 Last updated: Feb 11, 2025 Started: Apr 6, 2017 Primary completion: Dec 28, 2018 Completion: Mar 5, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on B Acute Lymphoblastic Leukemia and B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 34 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Jun 2017 · 3 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Apr 2018 · 3 months · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Feb 2019 · 4 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Aug 2019 · 5 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Mar 2020 · 5 months · monthly snapshot~Mar 2020 – ~Jul 2020 · 4 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Jun 2022 · 9 months · monthly snapshot~Jun 2022 – ~Apr 2024 · 22 months · monthly snapshot~Apr 2024 – ~Jun 2024 · 2 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Apr 2025 · 4 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

34 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Apr 2025 — Sep 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Dec 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 29 earlier versions

  1. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Apr 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Jun 2022 — Apr 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2021 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Feb 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Jul 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  9. Mar 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE2

  10. Oct 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2

  11. Aug 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

  12. Mar 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

  13. Feb 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Suspended → Active Not Recruiting

  14. Oct 2018 — Feb 2019 [monthly]

    Suspended PHASE2

    Status: Recruiting → Suspended

  15. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  16. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  17. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  18. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  19. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE2

  20. Jan 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

  21. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  22. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  23. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE2

  24. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  25. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  26. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

  27. Mar 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

  28. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE2

  29. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Columbus, United States , Duarte, United States , Fairway, United States , Jacksonville, United States , Kansas City, United States , Los Angeles, United States , Phoenix, United States , Rochester, United States , Salt Lake City, United States and 3 more locations